^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lazcluze (lazertinib) (EGFR inhibitor) + vabametkib (ABN401) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1174P - The MET inhibitor ABN401 in combination with the third-generation EGFR-TKI is effective MET-amplified and EGFR-mutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models
Published date:
09/05/2022
Excerpt:
The signal transduction inhibition and cytotoxic response of ABN401 in combination with Lazertinib were tested in vitro against Osimertinib-resistance NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010)....ABN401 showed preclinical anti-tumor activities combined with Lazertinib (a 3rd-generation EGFR-TKI) in an EGFR mutant NSCLC model with MET gene amplification both in vitro and in vivo.
